Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection

J. Kubeš, G. Karabanovich, ATQ. Cong, I. Melnikova, O. Lenčová, P. Kollárová, H. Bavlovič Piskáčková, V. Keresteš, L. Applová, LCM. Arrouye, JR. Alvey, J. Paluncic, TL. Witter, A. Jirkovská, J. Kuneš, P. Štěrbová-Kovaříková, CA. Austin, M....

. 2025 ; 16 (1) : 4928. [pub] 20250528

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25015637

Grant support
P30 GM124165 NIGMS NIH HHS - United States
S10 OD021527 NIH HHS - United States
startup funds Mayo Clinic

Topoisomerase II alpha and beta (TOP2A and TOP2B) isoenzymes perform essential and non-redundant cellular functions. Anthracyclines induce their potent anti-cancer effects primarily via TOP2A, but at the same time they induce a dose limiting cardiotoxicity through TOP2B. Here we describe the development of the obex class of TOP2 inhibitors that bind to a previously unidentified druggable pocket in the TOP2 ATPase domain to act as allosteric catalytic inhibitors by locking the ATPase domain conformation with the capability of isoform-selective inhibition. Through rational drug design we have developed topobexin, which interacts with residues that differ between TOP2A and TOP2B to provide inhibition that is both selective for TOP2B and superior to dexrazoxane. Topobexin is a potent protectant against chronic anthracycline cardiotoxicity in an animal model. This demonstration of TOP2 isoform-specific inhibition underscores the broader potential to improve drug specificity and minimize adverse effects in various medical treatments.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015637
003      
CZ-PrNML
005      
20250731091134.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-025-60167-9 $2 doi
035    __
$a (PubMed)40425539
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kubeš, Jan $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic $1 https://orcid.org/0000000205134847
245    10
$a Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection / $c J. Kubeš, G. Karabanovich, ATQ. Cong, I. Melnikova, O. Lenčová, P. Kollárová, H. Bavlovič Piskáčková, V. Keresteš, L. Applová, LCM. Arrouye, JR. Alvey, J. Paluncic, TL. Witter, A. Jirkovská, J. Kuneš, P. Štěrbová-Kovaříková, CA. Austin, M. Štěrba, T. Šimůnek, J. Roh, MJ. Schellenberg
520    9_
$a Topoisomerase II alpha and beta (TOP2A and TOP2B) isoenzymes perform essential and non-redundant cellular functions. Anthracyclines induce their potent anti-cancer effects primarily via TOP2A, but at the same time they induce a dose limiting cardiotoxicity through TOP2B. Here we describe the development of the obex class of TOP2 inhibitors that bind to a previously unidentified druggable pocket in the TOP2 ATPase domain to act as allosteric catalytic inhibitors by locking the ATPase domain conformation with the capability of isoform-selective inhibition. Through rational drug design we have developed topobexin, which interacts with residues that differ between TOP2A and TOP2B to provide inhibition that is both selective for TOP2B and superior to dexrazoxane. Topobexin is a potent protectant against chronic anthracycline cardiotoxicity in an animal model. This demonstration of TOP2 isoform-specific inhibition underscores the broader potential to improve drug specificity and minimize adverse effects in various medical treatments.
650    12
$a DNA-topoisomerasy typu II $x metabolismus $x chemie $7 D004250
650    _2
$a zvířata $7 D000818
650    12
$a inhibitory topoisomerasy II $x farmakologie $x chemie $7 D059005
650    12
$a antracykliny $x škodlivé účinky $x farmakologie $7 D018943
650    _2
$a proteiny vázající poly-ADP-ribosu $x antagonisté a inhibitory $x metabolismus $x chemie $7 D000075223
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    12
$a kardiotoxicita $x prevence a kontrola $7 D066126
650    12
$a kardiotonika $x farmakologie $x chemie $7 D002316
655    _2
$a časopisecké články $7 D016428
700    1_
$a Karabanovich, Galina $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Cong, Anh T Q $u Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, 55905, MN, USA $u Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, 55905, MN, USA $1 https://orcid.org/0000000193077741
700    1_
$a Melnikova, Iuliia $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Lenčová, Olga $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Kollárová, Petra $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic $1 https://orcid.org/0000000196739210
700    1_
$a Bavlovič Piskáčková, Hana $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic $1 https://orcid.org/0000000298177247 $7 uk20211117634
700    1_
$a Keresteš, Veronika $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Applová, Lenka $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Arrouye, Lise C M $u Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, 55905, MN, USA
700    1_
$a Alvey, Julia R $u Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, 55905, MN, USA $1 https://orcid.org/0000000165499816
700    1_
$a Paluncic, Jasmina $u Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, 55905, MN, USA $1 https://orcid.org/0000000334201532
700    1_
$a Witter, Taylor L $u Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, 55905, MN, USA $u Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, 55905, MN, USA $1 https://orcid.org/0000000330963011
700    1_
$a Jirkovská, Anna $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Kuneš, Jiří $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Štěrbová-Kovaříková, Petra $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic
700    1_
$a Austin, Caroline A $u Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK. caroline.austin@newcastle.ac.uk $1 https://orcid.org/0000000219215947
700    1_
$a Štěrba, Martin $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic. sterbam@lfhk.cuni.cz
700    1_
$a Šimůnek, Tomáš $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic. simunekt@faf.cuni.cz
700    1_
$a Roh, Jaroslav $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University; Hradec, Králové, 500 03, Czech Republic. rohj@faf.cuni.cz
700    1_
$a Schellenberg, Matthew J $u Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, 55905, MN, USA. schellenberg.matthew@mayo.edu $1 https://orcid.org/0000000170365943
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 16, č. 1 (2025), s. 4928
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40425539 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091129 $b ABA008
999    __
$a ok $b bmc $g 2366473 $s 1252762
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 16 $c 1 $d 4928 $e 20250528 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
GRA    __
$a P30 GM124165 $p NIGMS NIH HHS $2 United States
GRA    __
$a S10 OD021527 $p NIH HHS $2 United States
GRA    __
$a startup funds $p Mayo Clinic
LZP    __
$a Pubmed-20250708
Back

Find record

Citation metrics

Logged in users only

Archiving options